Collectively, hUC-MSCs significantly enhance the anti-tumor capability of CD19 CAR T-cells under high tumor burden conditions by inducing CD8<sup>+</sup> NK-like cytotoxic T lymphocytes through Th17 differentiation, while concurrently mitigating treatment-related side effects. The gene discussed is CD8A; the disease is neoplasm.